---
title: "CSPC PHARMA  9M Net Profit RMB7.076B Up 101.5% YoY"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305913083.md"
description: "CSPC PHARMA reported a 101.5% YoY increase in net profit to RMB7.076 billion for the first three quarters of 2026, with revenue up 27% to RMB25.26 billion. Underlying profit rose 134.5%. The company increased R&D expenses by 10.9%, funding significant progress including seven new product approvals in China and marketing approval in the EU for one self-developed drug."
datetime: "2026-11-18T04:23:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305913083.md)
  - [en](https://longbridge.com/en/news/305913083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305913083.md)
generator: "portal-rs"
---

# CSPC PHARMA  9M Net Profit RMB7.076B Up 101.5% YoY

CSPC PHARMA (01093.HK) -0.225 (-2.852%) Short selling $203.82M; Ratio 36.092% announced its results for the first three quarters ended September 2026. Revenue amounted to RMB25.26 billion, up 27% YoY. Net profit rose 101.5% YoY to RMB7.076 billion, with EPS at RMB0.6214. Excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation expenses, underlying profit for the first three quarters amounted to RMB7.22 billion, up 134.5% YoY.  

During the period, R&D expenses amounted to RMB4.643 billion, representing an increase of 10.9% compared with the same period last year, accounting for approximately 30.2% of finished drug business revenue.

Since the beginning of the year, the group's registration and approval progress in China included approval for the launch of seven new products; acceptance of marketing applications for 10 products; five breakthrough therapy designations granted; and 32 clinical trial approvals obtained. In overseas markets, the group also obtained 12 clinical trial approvals and one fast-track designation, while securing marketing approval in the European Union for one self-developed drug.(sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)

AASTOCKS Financial News

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Wins China Approval for First-in-Class Batoclimab Therapy in Myasthenia Gravis](https://longbridge.com/en/news/302792343.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [CSPC Starts Phase II Trial of New RSV Drug SYH2066 in China](https://longbridge.com/en/news/302701865.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**